Join CancerNetwork

Ensuring Holistic, Individualized Transitions of Care for Cancer Survivors

A panel of cancer survivorship experts outline major areas of focus and care models for improving outcomes among pediatric and adult survivors of cancer.

Andrew M. Evens, DO, MBA, MSc

Belantamab Mafodotin Regimen Improves OS in R/R Multiple Myeloma

Andrew M. Evens, DO, MBA, MSc, discusses the importance of meeting the emotional and physical needs of cancer survivors to help them lead fruitful lives.

$Findings from DREAMM-7 support belantamab mafodotin plus bortezomib and dexamethasone as a standard of care in relapsed/refractory multiple myeloma.$

Kristi Rosa

Managing Risks, Planning Treatment, & Making Progress in Pancreatic Cancer

Findings from DREAMM-7 support belantamab mafodotin plus bortezomib and dexamethasone as a standard of care in relapsed/refractory multiple myeloma.

A nurse practitioner discussed risk factors, diagnostic challenges, and treatment planning in patients with pancreatic cancers.

Kelley A. Rone, DNP, RN, AGNP-c

December 2nd 2024

Cardiac AEs Decrease With 2nd-Generation BTK Inhibitors in B-Cell Cancers

A nurse practitioner discussed risk factors, diagnostic challenges, and treatment planning in patients with pancreatic cancers.

Atrial fibrillation occur at a smaller likelihood with second-generation BTK inhibitors vs first-generation BTK inhibitors in B-cell hematologic cancers.

Ashley Chan

Uproleselan Does Not Reach OS End Point, Shows Select Efficacy in AML

Atrial fibrillation occur at a smaller likelihood with second-generation BTK inhibitors vs first-generation BTK inhibitors in B-cell hematologic cancers.

Jordyn Sava

Individually Optimizing Cancer Outcomes Through a Mission of Survivorship Care

Phase 3 data show meaningful benefits with uproleselan in patients with primary refractory AML and post-transplant survival.

Related Content

Russ Conroy

Ensuring Holistic, Individualized Transitions of Care for Cancer Survivors

A panel of cancer survivorship experts outline major areas of focus and care models for improving outcomes among pediatric and adult survivors of cancer.

Andrew M. Evens, DO, MBA, MSc

Belantamab Mafodotin Regimen Improves OS in R/R Multiple Myeloma

Andrew M. Evens, DO, MBA, MSc, discusses the importance of meeting the emotional and physical needs of cancer survivors to help them lead fruitful lives.

$Findings from DREAMM-7 support belantamab mafodotin plus bortezomib and dexamethasone as a standard of care in relapsed/refractory multiple myeloma.$

Kristi Rosa

Managing Risks, Planning Treatment, & Making Progress in Pancreatic Cancer

Findings from DREAMM-7 support belantamab mafodotin plus bortezomib and dexamethasone as a standard of care in relapsed/refractory multiple myeloma.

Kelley A. Rone, DNP, RN, AGNP-c

December 2nd 2024

Cardiac AEs Decrease With 2nd-Generation BTK Inhibitors in B-Cell Cancers

A nurse practitioner discussed risk factors, diagnostic challenges, and treatment planning in patients with pancreatic cancers.

Ashley Chan

Uproleselan Does Not Reach OS End Point, Shows Select Efficacy in AML

Atrial fibrillation occur at a smaller likelihood with second-generation BTK inhibitors vs first-generation BTK inhibitors in B-cell hematologic cancers.

Jordyn Sava